Alarmins differentially modulate airway contraction and relaxation of human small airways Authors: Joshua L. Kennedy, Dana N. Frederick, Reynold A. Panettieri, Cynthia J. Koziol-White Published: 2026 ABSTRACT Alarmins, including Thymic Stromal Lymphopoietin (TSLP) and Interleukins 33 and 25 (IL-33 and IL-25), contribute to the pathophysiology of allergic and nonallergic asthma by evoking exacerbations in response to allergens, viruses, and environmental irritants (as reviewed in [1]). Current evidence shows that inhibiting alarmins reduces symptoms and exacerbations in obstructive lung diseases, including asthma [1]. Preclinical work has largely focused on alarmins’ role in modulating airway inflammation, but far less is known about how alarmins regulate airway tone (contraction and relaxation). We posit that IL-33, TSLP, and IL-25 exert distinct effects on airway contraction and relaxation in airways from non-diseased subjects and those with asthma.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12931-026-03869-y. Methods Deidentified donor lungs were received at Rutgers University and the University of Arkansas for Medical Sciences/Arkansas Children’s Research Institute through partnerships with the National Disease Research Interchange, the International Institute for the Advancement of Medicine, and the Arkansas Regional Organ Recovery Agency. This work was not considered human subjects research by UAMS and Rutgers institutional review boards. Lungs were inflated with low-melting-temperature agarose, cooled, and sliced into sections containing cross-sectioned airways. Human precision cut lung slices (hPCLS) were generated from tissue cores containing small airways using a Compresstome Oscillating Vibratome (Precisionary Instruments, Ashland, MA), and viability was assessed as previously described [2, 3]. Slices were exposed to IL-33, TSLP, or IL-25 (R&D Systems, Minneapolis, MN) for 24 h before airway contraction to carbachol (Cch, 2 or 20 µM [Arkansas – Fig. 2 experiments], or 10− 8 – 10− 4 M, each dose every 10 min – [Rutgers – Fig. 1 experiments]) and relaxation to formoterol (Form, 10− 9 – 10− 4 M, each dose every 5 min – [Rutgers – Fig. 1 experiments]). Cch and Form were purchased from Sigma Aldrich (St. Louis, MO). Airway contraction was expressed as a percentage of baseline luminal area. Airway relaxation was expressed as a percentage of the pre-constricted airway luminal area. For full dose-response curves to Cch or Form, total integrated area under the curve (AUC) was calculated in Graphpad Prism 11 (Boston, MA) using the trapezoid rule using the equation \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\triangle\mathrm{X}\ast(\left[\left(\mathrm{Y1}+\mathrm{Y2}\right)/2\right]-\text{Baseline repeatedly for}$$\end{document}\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\text{adjacent pairs of points to define the curves}$$\end{document}. Statistical significance was determined using two-way ANOVA followed by pairwise Dunnett’s or Mann-Whitney post-tests, with p < 0.05 considered significant. All data is expressed as mean ± SEM. Representative hPCLS images for Fig. 1 are in the supplementary data as part of Fig. S1. Fig. 1IL-33, but not TSLP, enhances carbachol (Cch)-induced contraction and attenuates formoterol (Form)-induced relaxation of airways in human precision cut lung slices (hPCLS). hPCLS derived from non-diseased lung donors were exposed to TSLP (A, C) or IL-33 (B, D) (1-100 nM, 24 h) and airways contracted to a dose response of Cch (10− 8 – 10− 4 M) and relaxed to a dose response of formoterol (10− 9 – 10− 5 M). Area under the curve was calculated for each dose. TSLP: n = 3–18 donors; IL-33: 12–18 donors, *p < 0.05 by two-way ANOVA and Dunnett’s multiple comparison test. Data represents mean ± SEM IL-33, but not TSLP, enhances carbachol (Cch)-induced contraction and attenuates formoterol (Form)-induced relaxation of airways in human precision cut lung slices (hPCLS). hPCLS derived from non-diseased lung donors were exposed to TSLP (A, C) or IL-33 (B, D) (1-100 nM, 24 h) and airways contracted to a dose response of Cch (10− 8 – 10− 4 M) and relaxed to a dose response of formoterol (10− 9 – 10− 5 M). Area under the curve was calculated for each dose. TSLP: n = 3–18 donors; IL-33: 12–18 donors, *p < 0.05 by two-way ANOVA and Dunnett’s multiple comparison test. Data represents mean ± SEM Fig. 2IL-25, but not TSLP, enhances carbachol responsiveness of airways in asthma-derived hPCLS but not in non-diseased hPCLS. hPCLS from non-diseased and asthma donors were stimulated with IL-25 (A) or TSLP (B) (10 ng/ml, 24 h), and airway contraction to carbachol (Cch, 2 or 20 μm) was assessed. Airway contraction was expressed as % change in baseline luminal area. IL-25: n = 10 donors; TSLP: n = 7 donors; 71–157 slices, *p < 0.05 by two-tailed, unpaired Mann-Whitney test. Data represents mean ± SEM IL-25, but not TSLP, enhances carbachol responsiveness of airways in asthma-derived hPCLS but not in non-diseased hPCLS. hPCLS from non-diseased and asthma donors were stimulated with IL-25 (A) or TSLP (B) (10 ng/ml, 24 h), and airway contraction to carbachol (Cch, 2 or 20 μm) was assessed. Airway contraction was expressed as % change in baseline luminal area. IL-25: n = 10 donors; TSLP: n = 7 donors; 71–157 slices, *p < 0.05 by two-tailed, unpaired Mann-Whitney test. Data represents mean ± SEM Results In hPCLS derived from non-asthma donors, IL-33, but not TSLP, increased airway contraction (Fig. 1A, B). Only IL-33 at the highest dose (100 nM) increased airway sensitivity to Cch (LogEC50; Fig. S1). When assessing airway relaxation, IL-33 attenuated Form-mediated reversal of Cch-induced contraction (Fig. 1D inset) and decreased airway sensitivity to formoterol (LogEC50; Fig. S1). In contrast, TSLP had little effect on Form-mediated airway relaxation (Fig. 1C). Interestingly, IL-25 (10 ng/ml) had little impact on Cch-induced contraction in non-asthma-derived hPCLS, but increased Cch-induced contraction in asthma-derived hPCLS (Fig. 2A). TSLP (10 ng/ml) had little effect on contraction in either non-asthma or asthma-derived hPCLS (Fig. 2B). Discussion Controversy exists over whether alarmins directly affect airway smooth muscle (ASM) contraction [1, 4, 5], with some suggesting that ASM responses are secondary to interactions with immune cells. Our model lacks circulating immune cells, and many immune cells are removed in the process of hPCLS generation. Additionally, the culture conditions of the hPCLS are not conducive to immune cell survival. We previously published that ASM expresses low levels of alarmin receptors, with no detectable expression of CLRF2, a receptor for TSLP [6–8]. We acknowledge that the effects of alarmin exposure on bronchomotor tone may not mediated through direct stimulation of ASM, but rather are epithelial-directed, as epithelial cells have been not only shown to release alarmins, but also to respond to alarmin stimulation [9–12]. In our model, we observed that IL-33 and IL-25 increased airway contractility (Fig. 1). Notably, IL-33, but not TSLP, significantly reduced Form responsiveness, a long-acting β2-adrenergic receptor agonist widely used in asthma symptom management. The contraction of asthma-derived hPCLS compared with non-diseased hPCLS to IL-25 suggests heightened airway susceptibility to alarmins in asthma (Fig. 2). Notably, IL-33 exerted a pronounced effect in hPCLS from non-diseased donors. These findings have two key implications: (1) our hPCLS model can differentiate alarmin effects in airways from individuals with and without asthma; and (2) IL-33 alone diminishes bronchodilator responsiveness in non-diseased airways, showing it can alter bronchomotor tone. Although our platform lacks circulating immune cells, which may influence responses to alarmins, these data provide insight into how targeting these mediators may benefit patients with obstructive lung diseases such as asthma. Supplementary Information Supplementary Material 1. Supplementary Material 1.